Lilly Confident In Orforglipron Despite Disappointing Phase III Data

Oral GLP-1 Readout In Obesity Outweighed Q2 Earnings Beat

 
• By Mandy Jackson
  
Orforglipron still may be a blockbuster even if its data is not quite as strong as oral semaglutide (Shutterstock)

More from Earnings

More from Business